University of Michigan Rogel Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Michigan Rogel Cancer Center sits in the top decile of US sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count).
University of Michigan Rogel Cancer Center: 292 sponsored US clinical trials, 45 recruiting.
University of Michigan Rogel Cancer Center sponsors 292 registered US clinical trials on ClinicalTrials.gov, 45 of them currently recruiting, and 167 completed. 4 of these trials are in Phase 3-4 (later-stage) and 182 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
University of Michigan Rogel Cancer Center ranks in the top decile of sponsors by registered trial count (#118 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
167 of 229 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
292 total, page 5 of 6
Phase I/II Calcitriol in Lung Cancer
NCT00794547
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
NCT01028352
Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer
NCT01190527
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
NCT00743509
A Study of Changes in Hepatic Function During Radiation Therapy Using Hepatobiliary Single Photon Emission Tomography (SPECT)
NCT01519232
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
NCT00726180
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
NCT00724568
A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response
NCT01209962
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
NCT00726375
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma
NCT00644696
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
NCT00645333
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
NCT00645593
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
NCT00637390
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
NCT00615589
Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
NCT00585689
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
NCT00556452
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC
NCT00616109
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
NCT00573378
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
NCT00599131
Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure
NCT00555477
Early Assessment of Treatment Response Using Functional Diffusion Mapping
NCT02064283
Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer
NCT00603057
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
NCT00456599
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
NCT00565227
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
NCT00623935
A Study of Radiation Toxicity in the Liver Using MRI-Based Perfusion
NCT01210027
Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
NCT00480857
Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell Lymphoma
NCT00645359
A Pilot Study Assessing Intra-Metastasis Administration of Autologous KLH-pulsed Dendritic Cells With Tumoral Radiation Therapy in Patients With Metastatic Pancreatic Carcinoma
NCT00843830
Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy
NCT02679586
Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer
NCT00593866
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
NCT00405327
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
NCT00393796
A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
NCT00399321
Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer
NCT01663246
A Randomized Comparison of Radiation Therapy Techniques in the Management of Node Positive Breast Cancer
NCT00581256
A Study of Mitomycin C, Irinotecan, and Cetuximab
NCT00271011
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
NCT00239200
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
NCT00135200
Treatment for Patients With Metastatic Thyroid Cancer
NCT00176748
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
NCT00116961
Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas
NCT00148109
Tissue Procurement Protocol for Patients Undergoing Neoadjuvant Systemic Therapy for Breast Cancer
NCT00161265
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
NCT02031237
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer
NCT00156273
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
NCT00161278
Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation
NCT01519219
Vessel Sparing Prostate Radiation Therapy
NCT02958787
Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy
NCT00581529
MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier
NCT01988675
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 126 |
| Phase 3 | 2 |
| Phase 4 | 2 |
What is open in the University of Michigan Rogel Cancer Center pipeline
45 recruiting of 292 indexed (15% open); 167 completed (57%).
Phase mix: 4 late (III/IV) vs 182 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Michigan Rogel Cancer Center: open-pipeline peers nationwide
Peers matched on 292 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Michigan Rogel Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 292 trials (± recruiting share)
- Thomas Jefferson University · 292 trials · 18% recruiting
- University of Missouri-Columbia · 291 trials · 19% recruiting
- Kaiser Permanente · 294 trials · 7% recruiting
- Eisai · 287 trials · 2% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
Related
What to do with this University of Michigan Rogel Cancer Center page
292 registered trials is a research-attention snapshot, not an endorsement of University of Michigan Rogel Cancer Center or any single study.
- 45 of University of Michigan Rogel Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of Michigan Rogel Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Michigan Rogel Cancer Center pipeline card: 292 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.